Tingog Partylist, Roche sign pact for Mission Leapfrog 2030

• Tingog Partylist and Roche (Philippines) Inc. have signed a memorandum of  agreement (MOA) to advance the 2030 Mission Leapfrog Project (MLP), a collaboration of Roche and health ecosystems partners to accelerate transformation in healthcare outcomes for  women affected by breast and cervical cancer.

• Through the MOA, the Tingog-Roche partnership supports the goals of the National Integrated Cancer Control Act (NICCA) and the Universal Health Care Law (UHC) as it aims to advance breast and cervical cancer education, screening, diagnosis, and treatment to support women in key MLP sites.

MANILA, 28 May 2024 - To raise awareness of breast and cervical cancer and boost the capability of the government to give care and treatment to more women nationwide, Tingog Partylist and Roche (Philippines) Inc. signed a Memorandum of Agreement (MOA) on May 8, 2024 (Wednesday) to advance 2030 Mission Leapfrog Project (MLP).

The MOA cements a private-public sector partnership in support of the goals of the National Integrated Cancer Control Act (NICCA) and the Universal Healthcare Law (UHC), as 2030 Mission Leapfrog aims to improve healthcare outcomes in the Philippines, specifically those for breast and cervical cancer, through components such as education, screening, diagnostics, and treatment accessibility.

The parties formally signed the memorandum at the Office of Tingog Partylist at the House of Representatives in Quezon City through Tingog Partylist Rep. Rep. Jude Acidre; Dr. Diana Edralin, General Manager of Roche (Philippines) Inc.; and Dr. Ma. Teresa Dioko, Healthcare Ecosystems Chapter Lead of Roche (Philippines) Inc.

With the MOA, Tingog and Roche hope to speed up the transformation of healthcare outcomes in the country by improving the referral system from screening to treatment, through the lens of a breast or cervical cancer patient and through key partner local government units (LGUs). 

“With this agreement, we mark the beginning of a transformative journey with the 2030 Mission Leapfrog Project,” said Tingog Partylist Rep. Yedda Marie K. Romualdez in her message delivered by Rep. Acidre.

“At the heart of Tingog Partylist's mission is a steadfast commitment to championing the health and well-being of our people. Our core agenda has always been focused on fostering healthcare development that directly benefits the lives of those we serve,” she added. 

“Our partnership with Roche (Philippines) Inc. signifies a pivotal step towards realizing this vision. Roche's global expertise in healthcare innovation, combined with Tingog's deep understanding of the local landscape, creates a powerful synergy. Together, we are poised to make significant strides in improving the diagnosis and treatment of breast and cervical cancer, thereby enhancing the quality of life for countless individuals,” Rep. Romualdez said.

“Today marks a significant leap forward in our shared commitment to transforming health care outcomes, particularly in the realm of breast cancer and cervical cancer,” Rep. Acidre said. 

“Mission Leapfrog embodies a noble mission to accelerate the journey towards improved healthcare systems, focusing on the pivotal experiences of breast and cervical cancer patients. This initiative aims to revolutionize the landscape of women’s health,” he added.

“We thank Tingog Partylist and Reps. Yedda Romualdez and Jude Acidre for partnering with us in ensuring teachers, mothers, daughters, pillars of our society have access to life-saving medicines and diagnostics ,” said Dr. Edralin, who is also President of the Pharmaceutical and Healthcare Association of the Philippines (PHAP).

“We also thank House Speaker Ferdinand Martin G. Romualdez for helping us at Roche address the anxiety and confusion around breast and cervical cancer and empower women to take charge of their health through better education and prevention, and lessen the fear of the financial impact of cancer through government and private funding support,” added Dr. Dioko.

Under the collaborative agreement, Tingog and Roche will help advance breast and cervical cancer education, people gathering, diagnosis, and treatment support for the women in the Mission Leapfrog LGU sites, as they champion policies supporting cancer program prioritization and funding.

Roche will also bring in partners from various stakeholders who will support and develop the MLP, and help map out avenues to care and financing to minimize the out-of-pocket expenses of patients.

Apart from helping provide access to mammogram and breast ultrasound services to high-risk women identified by the Mission Leapfrog Program, Tingog will also help provide funding support for breast and cervical cancer diagnosis and cancer treatment.

Tingog Partylist is a political organization in the Philippines that focuses on advocating the marginalized sectors of society, particularly those in the Visayas region. The word "Tingog" means "voice" in Cebuano, reflecting the partylist's mission to amplify the voices of underrepresented communities in legislative matters. It focuses on advocating for the rights and welfare of farmers, fisherfolk, urban poor, women, indigenous peoples, and other marginalized groups.

For more information on Tingog Partylist, please visit www.tingog.ph, emailvisitor call

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the 15th consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. 

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. 

For more information, please visitAll trademarks used or mentioned in this release are protected by law.

Roche (Philippines) Inc.
Unit 801, 8th Floor, The Finance Centre,
9th Ave cor 26th St, Bonifacio Global City,
Taguig City, Metro Manila 1634,
Philippines
Trunk Line:

If you need further information, please consult your Healthcare Provider.

For medical information queries and product quality complaints, please email:

For suspected adverse drug reactions, please report to the Food and Drug Administration (FDA) at aand to the Roche (Philippines) Inc. Patient Safety at

Contact: Jimbo Owen Gulle, Communications and Corporate Affairs Manager, Roche (Philippines); Phone:/ e-mail: